Compare BioNano Genomics Inc (BNGO) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Expensify Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Expensify Inc trades at $2.27 (market cap $209.73M). The key difference: Expensify Inc is far larger — about 15.4× BioNano Genomics Inc's market cap, and Expensify Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | EXFY | |
|---|---|---|
Market Cap | $13.66M | $209.73M |
Sector | Health | Technology |
52-Week High | $4.92 | $2.69 |
52-Week Low | $1.06 | $0.75 |
Enterprise Value | $16.26M | $149.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Expensify (EXFY) trades at $2.22, down 10.12% in the past 24 hours, with a bullish technical signal from moving averages and a neutral RSI. Recent Q2 2026 earnings showed a beat on EPS and a return to non-GAAP profitability, with revenue of $33.9 million. The company is expanding its AI-native solutions and European card offerings, supported by positive cash flow trends.
Outlook is cautiously optimistic due to earnings improvements and strategic expansions, but risks include persistent net losses, high P/E ratio of 258.82, and competitive pressures in expense management software. Analyst consensus is mixed with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
